Indian Regulator Swings Into Action With New Rules On Clinical Trials, Biosimilars And Banning Of Drugs
This article was originally published in PharmAsia News
Executive Summary
Apparently under pressure to fast track policy reforms, the Indian drug regulator has come out with detailed rules that encompass new clinical trials, curbs on trials to be undertaken by investigators and provisions to get biosimilars approved for India.